1
Participants
Start Date
January 8, 2018
Primary Completion Date
April 1, 2020
Study Completion Date
April 1, 2020
BL-8040
Subjects will receive maintenance treatment consisting of subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
Atezolizumab
Subjects will receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on Day 2 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
Medical College of Wisconsin/Froedtert Hospital, Milwaukee
The University of Texas - Md Anderson Cancer Center - Leukemia Center, Houston
Fakultni Nemocnice Brno / University Hospital Brno Interni Hematologicka A Onkologicka Klinika / Internal Hematology and Oncology Clinic, Brno
Fakultni Nemocnice Ostrava (Fno) / University Hospital Ostrava Klinika Hematoonkologie / Hematooncology Clinic, Ostrava
Fakultni Nemocnice Kralovske Vinohrady Fnkv / University Hospital Kralovske Vinohrady Interní Hematologická Klinika Fnkv / Internal Hematology Clinic, Prague
Rambam Medical Center, Haifa
Shaarei Tzedek Medical Center, Jerusalem
Wojewódzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im. M. Kopernika W Lodzi, Lodz
Národný Onkologický Ústav / National Cancer Institute, Oddelenie Onkohematológie Ii / Department of Oncohematology Ii, Bratislava
Hospital San Pedro de Alcántara de Cáceres, Cáceres
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Fe de Valencia, Valencia
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
BioLineRx, Ltd.
INDUSTRY